Evidence synthesis · §4
Acute pancreatitis with incretin-based therapies — summary of findings
Outcome-by-outcome summary with effect, certainty and the reason for each downgrade.
§4Summary of findings
§4.1Summary of findings
Table 7. Summary of findings for Acute pancreatitis with incretin-based therapies.
| Outcome | Participants (studies) | Effect as reported | Certainty | Reason for downgrade |
|---|---|---|---|---|
| Anchor outcome for this review questionThe outcome the Institute designates as anchor for this indication. | 51,744 (24) | Moderate certainty evidence from the pooled cardiovascular outcome trials, in which pancreatitis was adjudicated and exposure was long, does not… | Moderate | publication bias |
| Discontinuation for adverse eventsReported as a summary-of-findings row rather than in a tolerability annex, following a public submission. | 44,634 (24) | Reported per contributing trial; see the included-studies table | Moderate | inconsistency |
| Serious adverse eventsEvent counts are low; the estimate is imprecise by construction. | 46,634 (22) | Reported per contributing trial; see the included-studies table | Low | risk of bias |
| Any adverse eventAscertained by spontaneous report in the contributing trials. | 40,005 (22) | Reported per contributing trial; see the included-studies table | Low | indirectness, publication bias |
| Certainty ratings describe confidence in the effect estimate for the stated outcome. They are not recommendations and do not transfer between outcomes. | ||||
§4.2Forest plot
Study estimatePooled estimate
§4.3Certainty assessment for the anchor outcome
Table 8. Reasoning recorded against each certainty domain for the anchor outcome.
| Domain | Rating | Reasoning |
|---|---|---|
| Risk of bias | No concern | No serious concern identified in this domain. |
| Inconsistency | No concern | No serious concern identified in this domain. |
| Indirectness | No concern | No serious concern identified in this domain. |
| Imprecision | No concern | No serious concern identified in this domain. |
| Publication bias | Serious | Registered trials without posted results were identified for this question. |
| Overall: Moderate certainty. The true effect is likely to be close to the estimate, but there is a possibility that it is substantially different. Further research is likely to have an important impact on confidence in the estimate. | ||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 2023;330(18):1795–1797. doi:10.1001/jama.2023.19574 · PMID 37796527
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-ES-025/4 · https://compoundevidence.com/syntheses/pancreatitis-risk-incretins/summary-of-findings/ · retrieved 30 July 2026